Efficacy and safety of direct oral anticoagulants for preventing venous thromboembolism in hospitalized cancer patients: a national multicenter retrospective cohort study
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction Studies on the use of direct oral anticoagulants (DOACs) for preventing venous thromboembolism (VTE) in hospitalized cancer patients are lacking. Therefore, we conducted a multicenter retrospective cohort study to evaluate the efficacy and safety of DOACs versus low-molecular-weight heparin (LMWH) for the primary prevention of VTE in hospitalized cancer patients. Methods Clinical outcomes included thrombosis, VTE, other thrombosis, all bleeding, major bleeding, nonmajor bleeding, and all-cause death. A 1:1 cohort of rivaroxaban and LMWH patients was created by propensity score matching. Results A total of 2,385 cancer patients were included in this study. During the 3-month follow-up period, 129 (5.4%) thrombosis events occurred, 63 (2.7%) of which were VTEs and 66 (2.8%) of which were other thrombosis events. All bleeding occurred in 163 (6.8%) patients, 68 (2.9%) had major bleeding, and 95 (4.0%) had nonmajor bleeding. All-cause deaths occurred in 113 (4.7%) patients. After adjusting for various confounders, the incidence of thrombosis and other thromboses was significantly lower in the rivaroxaban group than in the LMWH group [OR 0.543, 95% CI (0.343–0.859), p = 0.009; OR 0.461, 95% CI (0.241–0.883), p = 0.020]. There were no significant differences in incidence of VTE, total bleeding, major bleeding, nonmajor bleeding, or all-cause death. Conclusion In oncology patients receiving thromboprophylaxis, rivaroxaban has a lower incidence of thrombosis and other thrombosis and a similar incidence of VTE as LMWH and does not increase the risk of bleeding. Rivaroxaban may be an attractive alternative to LMWH for preventing VTE in hospitalized cancer patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Efficacy and safety of direct oral anticoagulants for preventing venous thromboembolism in hospitalized cancer patients: a national multicenter retrospective cohort study
- Date Crossref
- 05/07/2024
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Fujian Medical University Department of Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
Longyan University pays non établi dans la noticeUniversité ou école supérieure
-
Shanghai Sixth People's Hospital Department of Pharmacy pays non établi dans la noticeÉtablissement de santé
-
Nanjing Medical University Department of Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
First Affiliated Hospital of Fujian Medical University pays non établi dans la noticeÉtablissement de santé
-
Xian Yang Central Hospital pays non établi dans la noticeÉtablissement de santé
-
Xi'an Jiaotong University pays non établi dans la noticeUniversité ou école supérieure
-
Dalian Medical University Department of Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
Second Affiliated Hospital of Dalian Medical University pays non établi dans la noticeÉtablissement de santé
-
Yuncheng University pays non établi dans la noticeUniversité ou école supérieure
-
Shanxi Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Yuncheng Central Hospital Department of Pharmacy pays non établi dans la noticeÉtablissement de santé
Department of Pharmacy — Fujian Medical University, Longyan University et Department of Pharmacy — Shanghai Sixth People's Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.